Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

Aureon Laboratories (New York, NY) a commercial-stage diagnostic company focused on prognostic assays for prostate cancer and PSA, closed a $7M Series D financing. Participants have included Atlas Venture, New Leaf Venture Partners, Sprout Group and Pfizer.

Tragara Pharmaceuticals (San Diego, CA) a clinical-stage biopharmaceutical company focused on selective biomarker for oncology, pain and inflammation therapeutics, closed a $5M Series B financing. Participants include Domain Associates, Mitsubishi Corp., Morgethaler Ventures, Oxford Bioscience Partners and ProQuest Investments.

Direvo (Germany) a commercial-stage enzyme engineering and strain development platform for industrial biotechnology applications, closed a $8.1M Series D financing. Participants include TVM Capital and NRW Bank.

Oxford Nanopore Technologies (United Kingdom) a development-stage medical device company focused on DNA sequencing via an electronic, label-free analysis of single molecule platform, closed a $28M Series C financing. Participants include Lansdowne Partners, IP Group, Invesco Perpetual and Illumina.

Tioga Pharmaceuticals (San Diego, CA) a clinical-stage small molecule company focused on diarrhea predominant Irritable Bowel Syndrome, closed a $18M Series C financing. Participants include Forward Ventures, New Leaf Venture Partners, BB Biotech Ventures and Genesys Capital.

PolyTherics (United Kingdom) a clinical-stage protein engineering company focused on site-specific PEGylation of biologics, closed a $4M Series C financing. Participants include Imperial Innovations, Longbow Capital and The Capital Fund.

Intercept Pharmaceuticals (New York, NY) a clinical-stage small molecule drug company focused on modulation of bile acid signaling in primary biliary cirrhosis and type II diabetics with fatty acid liver disease, closed a $25M Series B financing. Participants include Genextra.

Liquidia (Morrisville, NC) a development-stage company focused on improving delivery of inhaled therapeutics and vaccines via nanoparticles with optimized characteristics for increased target specificity, closed a $13M Series C financing, bringing the total round to $20M. Participants include Canaan Partners, Pappas Ventures, New Enterprise Associates, Morningside and Firelake Capital.

Juvaris BioTherapeutics (Burlingame, CA) a clinical-stage biopharma company focused on adjuvanted vaccines for seasonal flu and immunotherapeutics for Leukemia and animal health, closed a $12.5M Series B financing, bringing the total round to $25M. Participants include Kleiner Perkins Caufield & Byers, SV Life Sciences and an undisclosed corporate partner.

GlobeImmune (Lousiville, CO) a clinical-stage biopharmaceutical company developing a therapeutic vaccine platform focused on pancreatic cancer and hepatitis C, Closed a $17.5M Series E financing. Participants include Generali Financial Holding, BSI, Celgene, Wexford Capital, Mellon Family Investment Company, Eminent Venture Capital, Boston Life Science Venture, WRF Capital, Partners Healthcare, Yasuda, Genentech, Biogen Idec, CIDC, PAC-LINK […]

Bind Biosciences (Cambridge, MA) a preclinical-stage biopharmaceutical company focused on differential medicinal nanoengineered delivery of targeted therapeutics and controlled drug exposure to diseased tissue for various cancers, closed an $11M Series C financing. Participants have included DHK Investments, ARCH Venture Partners, Flagship Ventures, NanoDimension and Polaris Venture Partners.

Rapid Diagnostek (Hudson, WI) a development-stage medical device company focused on vitro diagnostics using radio frequency phase shift technology for virus detection in fluid samples, closed a $4M Series B financing. Participants include Peak Ridge Capital.

Genomatica (San Diego, CA) a development-stage biofuel company focused on methods for adaptive evolution of microbes to achieve optimal performance under process conditions to produce industrial chemicals from carbohydrates, closed a $15M Series C financing. Participants include TPG Biotech, Mohr Davidow Ventures, Alloy Ventures and Draper Fisher Jurvetson.

« Previous Entries  Next Page »

to top of page...